详情页 - 昆明医科大学第一附属医院知识库

当前位置：首页 > 详情页

Multi-cohort analysis reveals altered archaea in colorectal cancer fecal samples across populations

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong [2]Department of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Yunnan Province Clinical Research Center for Digestive Disease, Yunan Geriatric Medical Center, China [3]Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

出处：

DOI：

ISSN：

关键词： Archaea Colorectal Cancer Biomarker Methanobrevibacter_A smithii

摘要：

Archaea are important components of the host microbiome, but their roles in colorectal cancer (CRC) remain largely unclear. We aimed to elucidate the contribution of gut archaea to CRC across multiple populations.This study incorporated fecal metagenomic data from 10 independent cohorts from 7 countries and an additional in-house cohort, totaling 2101 metagenomes (748 CRC, 471 adenoma, and 882 healthy controls (HC)). Taxonomic profiling was performed using Kraken2 against the Genome Taxonomy Database. Alterations of archaeal communities and their interactions with bacteria and methanogenic functions were analyzed. Random Forest model was used to identify multicohort diagnostic microbial biomarkers in CRC.The overall archaeal alpha diversity shifted from HC, adenoma patients to CRC patients with Methanobacteriota phylum enriched while order Methanomassiliicoccales depleted. At the species level, Methanobrevibacter_A smithii and Methanobrevibacter_A sp002496065 were enriched, while 8 species, including Methanosphaera stadtmanae and Methanomassiliicoccus_A intestinalis, were depleted in CRC patients across multiple cohorts. Among them, M. stadmanae, Methanobrevibacter_A sp900314695 and Methanocorpusculum sp001940805 exhibited a progressive decrease in the HC-adenoma-CRC sequence. CRC-depleted methanogenic archaea exhibited enhanced co-occurring interactions with butyrate-producing bacteria. Consistently, methanogenesis-related genes and pathways were enriched in CRC patients. A model incorporating archaeal and bacterial biomarkers outperformed single-kingdom models in discriminating CRC patients from healthy individuals with AUC ranging from 0.744 to 0.931 in leave-one-cohort-out analysis.This multicohort analysis uncovered significant alterations in gut archaea and their interactions with bacteria in healthy individuals, adenoma patients and CRC patients. Archaeal biomarkers, combined with bacterial features, have potential as non-invasive diagnostic biomarkers for CRC.Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区胃肠肝病学

第一作者：

第一作者机构： [1]Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Regulatory effect of wee1 on proliferation of colorectal cancer cells [2]SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study [3]RNF114 facilitates the proliferation, stemness, and metastasis of colorectal cancer [4]Hereditary nonpolyposis colorectal cancer(Open Access) [5]结直肠癌CpG岛甲基化表型的研究进展 [6]Identification of prognostic biomarkers in colorectal cancer using a long non-coding RNA-mediated competitive endogenous RNA network [7]A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer [8]DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors [9]Colorectal Cancer Genetic Heterogeneity Delineated by Multi-Region Sequencing [10]DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.